Zynerba Pharmaceuticals Announces Oral Presentations at the Virtual American Academy of Child and Adolescent Psychiatry (AACAP) 2020 Annual Meeting


DEVON, Pa., Oct. 08, 2020 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced the acceptance and oral presentation details of two sets of data at the virtual American Academy of Child and Adolescent Psychiatry (AACAP) 2020 Annual Meeting. The oral presentations will take place during the “Research Pipeline: New Findings on Diagnostic and Therapeutics” session. The AACAP annual meeting is being held virtually from October 12th through October 24th, 2020. A copy of the slides will be made available on Friday October 23rd at the time of presentation on the Zynerba corporate website at http://zynerba.com/publications/.

See the article here:
Zynerba Pharmaceuticals Announces Oral Presentations at the Virtual American Academy of Child and Adolescent Psychiatry (AACAP) 2020 Annual Meeting

Related Posts